Autoantibodies and decreased expression of the transcription factor ELF-3 together with increased chemokine pathways support an autoimmune phenotype and altered differentiation in lichen planus located in oral mucosa

Journal of the European Academy of Dermatology and Venereology

Volumn 27, Issue 11, 2013, Pages 1410-1416

  Danielsson, K ^a   Boldrup, L ^a   Rentoft, M ^a   Coates, P J ^b   Ebrahimi, M ^a   Nylander, E ^a   Wahlin, Y B ^a   Nylander, K ^a  

^a UMEÅ UNIVERSITY   (Sweden)

^b UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; CHEMOKINE RECEPTOR CXCR3; CXCL11 CHEMOKINE; GAMMA INTERFERON INDUCIBLE PROTEIN 10; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR ELF 3; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; AUTOIMMUNE DISEASE; CELL DIFFERENTIATION; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE EXPRESSION; HISTOLOGY; HUMAN; HUMAN TISSUE; KERATINOCYTE; LASER MICRODISSECTION; LICHEN PLANUS; LICHEN SCLEROSUS ET ATROPHICUS; MALE; MOUTH LICHEN PLANUS; MOUTH MUCOSA; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PUNCH BIOPSY; QUANTITATIVE ANALYSIS; REGULATORY MECHANISM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TISSUE DISTRIBUTION; WESTERN BLOTTING;

ADULT; AGED; AGED, 80 AND OVER; AUTOANTIBODIES; BASE SEQUENCE; BLOTTING, WESTERN; CHEMOKINES; DNA PRIMERS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; LICHEN PLANUS, ORAL; MALE; MIDDLE AGED; PHENOTYPE; POLYMERASE CHAIN REACTION;

EID: 84885948960     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/jdv.12027     Document Type: Article

References (43)

1. Roopashree MR, Gondhalekar RV, Shashikanth MC, et al. Pathogenesis of oral lichen planus - a review. J Oral Pathol Med 2010; 39: 729-734.
2. Axell T, Rundquist L,. Oral lichen planus - a demographic study. Community Dent Oral Epidemiol 1987; 15: 52-56.
3. Eisen D,. The clinical features, malignant potential, and systemic associations of oral lichen planus: a study of 723 patients. J Am Acad Dermatol 2002; 46: 207-214.
4. Sugerman PB, Satterwhite K, Bigby M,. Autocytotoxic T-cell clones in lichen planus. Br J Dermatol 2000; 142: 449-456.
5. Sugerman PB, Savage NW, Walsh LJ, et al. The pathogenesis of oral lichen planus. Crit Rev Oral Biol Med 2002; 13: 350-365.
6. Terlou A, Santegoets LA, van der Meijden WI, et al. An autoimmune phenotype in vulvar lichen sclerosus and lichen planus: a Th1 response and high levels of microRNA-155. J Invest Dermatol 2012; 132: 658-666.
7. Sallusto F, Lanzavecchia A,. Understanding dendritic cell and T-lymphocyte traffic through the analysis of chemokine receptor expression. Immunol Rev 2000; 177: 134-140.
8. Tensen CP, Flier J, Rampersad SS, et al. Genomic organization, sequence and transcriptional regulation of the human CXCL 11(1) gene. Biochim Biophys Acta 1999; 1446: 167-172.
9. Tensen CP, Flier J, Van Der Raaij-Helmer EM, et al. Human IP-9: a keratinocyte-derived high affinity CXC-chemokine ligand for the IP-10/Mig receptor (CXCR3). J Invest Dermatol 1999; 112: 716-722.
10. Iijima W, Ohtani H, Nakayama T, et al. Infiltrating CD8 + T cells in oral lichen planus predominantly express CCR5 and CXCR3 and carry respective chemokine ligands RANTES/CCL5 and IP-10/CXCL10 in their cytolytic granules: a potential self-recruiting mechanism. Am J Pathol 2003; 163: 261-268.
11. Flier J, Boorsma DM, van Beek PJ, et al. Differential expression of CXCR3 targeting chemokines CXCL10, CXCL9, and CXCL11 in different types of skin inflammation. J Pathol 2001; 194: 398-405.
12. Lo Muzio L, Mignogna MD, Favia G, et al. The possible association between oral lichen planus and oral squamous cell carcinoma: a clinical evaluation on 14 cases and a review of the literature. Oral Oncol 1998; 34: 239-246.
13. Rodstrom PO, Jontell M, Mattsson U, et al. Cancer and oral lichen planus in a Swedish population. Oral Oncol 2004; 40: 131-138.
14. Pakfetrat A, Javadzadeh-Bolouri A, Basir-Shabestari S, et al. Oral Lichen Planus: a retrospective study of 420 Iranian patients. Med Oral Patol Oral Cir Bucal 2009; 14: E315-E318.
15. Bermejo-Fenoll A, Sanchez-Siles M, Lopez-Jornet P, et al. Premalignant nature of oral lichen planus. A retrospective study of 550 oral lichen planus patients from south-eastern Spain. Oral Oncol 2009; 45: e54-e56.
16. Carbone M, Arduino PG, Carrozzo M, et al. Course of oral lichen planus: a retrospective study of 808 northern Italian patients. Oral Dis 2009; 15: 235-243.
17. Ingafou M, Leao JC, Porter SR, et al. Oral lichen planus: a retrospective study of 690 British patients. Oral Dis 2006; 12: 463-468.
18. Hsue SS, Wang WC, Chen CH, et al. Malignant transformation in 1458 patients with potentially malignant oral mucosal disorders: a follow-up study based in a Taiwanese hospital. J Oral Pathol Med 2007; 36: 25-29.
19. Bloor BK, Seddon SV, Morgan PR,. Gene expression of differentiation- specific keratins (K4, K13, K1 and K10) in oral non-dysplastic keratoses and lichen planus. J Oral Pathol Med 2000; 29: 376-384.
20. Ebrahimi M, Boldrup L, Wahlin YB, et al. Decreased expression of the p63 related proteins beta-catenin, E-cadherin and EGFR in oral lichen planus. Oral Oncol 2008; 44: 634-638.
21. Koster MI, Roop DR,. Mechanisms regulating epithelial stratification. Annu Rev Cell Dev Biol 2007; 23: 93-113.
22. Ebrahimi M, Wahlin YB, Coates PJ, et al. Decreased expression of p63 in oral lichen planus and graft-vs.-host disease associated with oral inflammation. J Oral Pathol Med 2006; 35: 46-50.
23. Ebrahimi M, Wahlin YB, Coates PJ, et al. Detection of antibodies against p63 and p73 isoforms in sera from patients diagnosed with oral lichen planus. J Oral Pathol Med 2007; 36: 93-98.
24. Ebrahimi M, Nylander E, Backlund B, et al. The use of a novel ELISA method for detection of antibodies against p63 in sera from patients diagnosed with oral and/or genital and skin lichen planus. J Oral Pathol Med 2010; 39: 486-490.
25. Oettgen P, Alani RM, Barcinski MA, et al. Isolation and characterization of a novel epithelium-specific transcription factor, ESE-1, a member of the ets family. Mol Cell Biol 1997; 17: 4419-4433.
26. Chang CH, Scott GK, Kuo WL, et al. ESX: a structurally unique Ets overexpressed early during human breast tumorigenesis. Oncogene 1997; 14: 1617-1622.
27. Andreoli JM, Jang SI, Chung E, et al. The expression of a novel, epithelium-specific ets transcription factor is restricted to the most differentiated layers in the epidermis. Nucleic Acids Res 1997; 25: 4287-4295.
28. Tymms MJ, Ng AY, Thomas RS, et al. A novel epithelial-expressed ETS gene, ELF3: human and murine cDNA sequences, murine genomic organization, human mapping to 1q32.2 and expression in tissues and cancer. Oncogene 1997; 15: 2449-2462.
29. He J, Pan Y, Hu J, et al. Profile of Ets gene expression in human breast carcinoma. Cancer Biol Ther 2007; 6: 76-82.
30. Grall F, Gu X, Tan L, et al. Responses to the proinflammatory cytokines interleukin-1 and tumor necrosis factor alpha in cells derived from rheumatoid synovium and other joint tissues involve nuclear factor kappaB-mediated induction of the Ets transcription factor ESE-1. Arthritis Rheum 2003; 48: 1249-1260.
31. Grall FT, Prall WC, Wei W, et al. The Ets transcription factor ESE-1 mediates induction of the COX-2 gene by LPS in monocytes. FEBS J 2005; 272: 1676-1687.
32. Rudders S, Gaspar J, Madore R, et al. ESE-1 is a novel transcriptional mediator of inflammation that interacts with NF-kappa B to regulate the inducible nitric-oxide synthase gene. J Biol Chem 2001; 276: 3302-3309.
33. van der Meij EH, van der Waal I,. Lack of clinicopathologic correlation in the diagnosis of oral lichen planus based on the presently available diagnostic criteria and suggestions for modifications. J Oral Pathol Med 2003; 32: 507-512.
34. Rentoft M, Hultin S, Coates PJ, et al. Tubulin alpha-6 chain is a stably expressed reference gene in archival samples of normal oral tissue and oral squamous cell carcinoma. Exp Ther Med 2010; 1: 419-423.
35. Wenzel J, Tuting T,. An IFN-associated cytotoxic cellular immune response against viral, self-, or tumor antigens is a common pathogenetic feature in "interface dermatitis". J Invest Dermatol 2008; 128: 2392-2402.
36. Iwai S, Amekawa S, Yomogida K, et al. ESE-1 inhibits the invasion of oral squamous cell carcinoma in conjunction with MMP-9 suppression. Oral Dis 2008; 14: 144-149.
37. Lyons JG, Patel V, Roue NC, et al. Snail up-regulates proinflammatory mediators and inhibits differentiation in oral keratinocytes. Cancer Res 2008; 68: 4525-4530.
38. Vincent T, Neve EP, Johnson JR, et al. A SNAIL1-SMAD3/4 transcriptional repressor complex promotes TGF-beta mediated epithelial-mesenchymal transition. Nat Cell Biol 2009; 11: 943-950.
39. Danielsson K, Wahlin YB, Coates PJ, et al. Increased expression of Smad proteins, and in particular Smad3, in oral lichen planus compared to normal oral mucosa. J Oral Pathol Med 2010; 39: 639-644.
40. Zhan Y, Yuan L, Kondo M, et al. The counter-regulatory effects of ESE-1 during angiotensin II-mediated vascular inflammation and remodeling. Am J Hypertens 2010; 23: 1312-1317.
41. Xu N, Brodin P, Wei T, et al. MiR-125b, a microRNA downregulated in psoriasis, modulates keratinocyte proliferation by targeting FGFR2. J Invest Dermatol 2011; 131: 1521-1529.
42. Zhang WY, Liu W, Zhou YM, et al. Altered microRNA expression profile with miR-27b down-regulation correlated with disease activity of oral lichen planus. Oral Dis 2012; 18: 265-270.
43. Danielsson K, Wahlin YB, Gu X, et al. Altered expression of miR-21, miR-125b, and miR-203 indicates a role for these microRNAs in oral lichen planus. J Oral Pathol Med 2012; 41: 90-95.